NBC Securities Inc. Buys 485 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

NBC Securities Inc. lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 58.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,309 shares of the biopharmaceutical company’s stock after acquiring an additional 485 shares during the period. NBC Securities Inc.’s holdings in TG Therapeutics were worth $30,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Creative Planning grew its stake in TG Therapeutics by 19.2% during the 3rd quarter. Creative Planning now owns 55,832 shares of the biopharmaceutical company’s stock worth $1,306,000 after buying an additional 8,993 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in TG Therapeutics in the 3rd quarter worth $53,000. Valeo Financial Advisors LLC acquired a new stake in TG Therapeutics during the 3rd quarter worth about $239,000. Daymark Wealth Partners LLC grew its stake in TG Therapeutics by 73.7% during the 3rd quarter. Daymark Wealth Partners LLC now owns 40,811 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 17,311 shares during the last quarter. Finally, Handelsbanken Fonder AB increased its holdings in TG Therapeutics by 22.6% in the 3rd quarter. Handelsbanken Fonder AB now owns 49,900 shares of the biopharmaceutical company’s stock worth $1,167,000 after buying an additional 9,200 shares during the period. Institutional investors own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TGTX shares. HC Wainwright reissued a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a report on Wednesday, September 18th. The Goldman Sachs Group increased their price target on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, B. Riley boosted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.83.

TG Therapeutics Trading Up 4.5 %

TGTX stock opened at $24.37 on Tuesday. TG Therapeutics, Inc. has a 12-month low of $6.52 and a 12-month high of $26.41. The business’s 50-day moving average is $23.19 and its 200 day moving average is $19.39. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of 105.96 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.08. The firm had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The firm’s revenue for the quarter was up 357.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.34) earnings per share. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.